0.782
-0.04 (-4.85%)
| Previous Close | 0.822 |
| Open | 0.830 |
| Volume | 161,343 |
| Avg. Volume (3M) | 230,517 |
| Market Cap | 38,962,504 |
| Price / Sales | 4.08 |
| Price / Book | 4.71 |
| 52 Weeks Range | |
| Earnings Date | 14 Aug 2025 |
| Profit Margin | -114.67% |
| Operating Margin (TTM) | -193.29% |
| Diluted EPS (TTM) | -0.230 |
| Quarterly Revenue Growth (YOY) | 0.70% |
| Total Debt/Equity (MRQ) | 27.66% |
| Current Ratio (MRQ) | 2.13 |
| Operating Cash Flow (TTM) | -4.88 M |
| Levered Free Cash Flow (TTM) | -2.66 M |
| Return on Assets (TTM) | -83.48% |
| Return on Equity (TTM) | -265.18% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Bearish | Bearish |
| Medical Devices (Global) | Bearish | Bearish | |
| Stock | NeuroOne Medical Technologies C | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | -2.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 3.5 |
| Technical Oscillators | -2.5 |
| Average | -0.75 |
|
NeuroOne Medical Technologies Corp operates as a medical technology company. It is focused on the development and commercialization of thin-film electrode technology for continuous electroencephalogram (cEEG) and stereoelectrocencephalography (sEEG) recording, brain stimulation, and ablation solutions for patients suffering from brain-related disorders. The company business is in one operating segment, which is the business of development and commercialization of products related to comprehensive neuromodulation cEEG and sEEG recording, monitoring, ablation, and brain stimulation solutions. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Small Growth |
| % Held by Insiders | 11.56% |
| % Held by Institutions | 10.96% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Princeton Global Asset Management Llc | 30 Jun 2025 | 16,833 |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 18 Aug 2025 | Announcement | NeuroOne® Receives FDA 510(k) Clearance for OneRF® Trigeminal Nerve Ablation System to Treat Facial Pain |
| 14 Aug 2025 | Announcement | NeuroOne® Reports Third Quarter Fiscal Year 2025 Financial Results; Revenue Increases 105% YoY and Gross Margin Expands to 53.9% |
| 31 Jul 2025 | Announcement | NeuroOne® to Report Third Quarter Fiscal Year 2025 Financial Results on Thursday, August 14 at 8:30 a.m. Eastern Time |
| 23 Jul 2025 | Announcement | NeuroOne® Receives Notice of Allowance for Key Patent from U.S. Patent & Trademark Office |
| 23 Jun 2025 | Announcement | NeuroOne® Patient Surpasses One Year Milestone of Seizure Freedom Following Treatment with OneRF® Ablation System |
| 03 Jun 2025 | Announcement | NeuroOne Strengthens Leadership Team with Appointment of Emily Johns as General Counsel and Corporate Secretary |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |